While they have shown good effects against specific solid tumors and leukemias as mono-therapeutics [247], they can also sensitize cells to death in combined therapeutic regimens, as seen with temozolomide [248], cytarabine [249], prednisolone [250] and even the pro-inflammatory cytokine TNF-α [251, 252], in a variety of cell types (Table 7). This evidence concerns the gene TNF and leukemia.